## Clinical Context: Thyroglobulin-Positive, Iodine-Negative Recurrence This patient represents a challenging scenario in thyroid cancer surveillance: **biochemical recurrence** (elevated thyroglobulin) with **negative radioiodine imaging**. This indicates **iodine-non-avid disease** — a hallmark of more aggressive or dedifferentiated PTC. ## Why FDG-PET Is Superior Here **Key Point:** In iodine-negative recurrent PTC, FDG-PET has superior sensitivity (80–90%) compared to radioiodine scintigraphy (which is negative by definition in this scenario) or conventional imaging alone. **Mechanism:** Dedifferentiated or aggressive PTC cells lose the ability to concentrate iodine but retain elevated glucose metabolism. FDG-PET exploits this metabolic shift and can detect: - Lymph node metastases (especially in the mediastinum and distant nodes) - Lung micrometastases - Bone lesions - Soft tissue recurrence ## Why Each Alternative Fails | Investigation | Limitation | |---|---| | **Repeat RAI scintigraphy** | Patient is already iodine-negative; higher activity will not improve detection of non-avid disease. Repeating a negative test is futile. | | **Contrast-enhanced CT** | Useful for anatomical detail but lower sensitivity for small metastases and micrometastatic disease compared to FDG-PET. Often used *after* PET to characterize lesions. | | **TSH suppression + repeat Tg** | Appropriate for monitoring *known* disease but does not localize the site of recurrence. Delays diagnosis of potentially aggressive disease. | ## Clinical Algorithm for Tg-Positive, RAI-Negative PTC ```mermaid flowchart TD A["PTC post-thyroidectomy + RAI"]:::outcome --> B{"Rising thyroglobulin?"}:::decision B -->|Yes| C{"RAI scintigraphy positive?"}:::decision C -->|Yes| D["Iodine-avid disease"]:::outcome D --> E["Repeat RAI or consider surgery"]:::action C -->|No| F["Iodine-non-avid disease"]:::outcome F --> G["FDG-PET/CT"]:::action G --> H{"Lesion detected?"}:::decision H -->|Yes| I["Localize & plan intervention"]:::action H -->|No| J["Micrometastatic disease or low-volume recurrence"]:::outcome J --> K["Consider TSH suppression, tyrosine kinase inhibitor, or repeat imaging"]:::action ``` **High-Yield:** FDG-PET/CT is the **gold standard** for localizing iodine-negative recurrent PTC. It changes management in ~40% of cases by identifying previously undetected metastases. **Clinical Pearl:** Thyroglobulin >10 ng/mL with negative imaging has ~90% likelihood of metastatic disease; FDG-PET will identify the site in most cases. ## Suppression Therapy Rationale TSH suppression (levothyroxine to suppress TSH <0.1 mIU/L) is used for **long-term management** of known disease to slow growth, but it does NOT localize recurrence and should not delay diagnostic imaging in a patient with biochemical evidence of active disease.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.